|
| Publication Date | Author | Experiment group (n) | Control group (n) | Treatments versus Control | Age of experiment group | Age of control | Diagnosis | Diagnosis criteria | Experiment Events | Control Events | Treatment Duration | Jadad | Gender | Nation | Side Effect€ | Side Effect © | Assessment tool |
|
| 2015 | LI Xueqing | 30 | 30 | NS/pinaverium bromide 50mg tid | 46±16 | 44±16 | IBS-D | ROME III | 28 | 24 | 8 weeks | 2 | Mixed | China | 0 | 0 | symptom assessment tool (China) (4 points) |
| 2014 | Zhan Daowei | 29 | 28 | (LR3, ST36,SP6,ST25, ST37,GV20,EX-HN3)/pinaverium bromide 50mg tid | 42±14 | 37±13 | IBS-D | ROME III | 26 | 19 | 4 weeks | 3 | Mixed | China | 0 | 0 | symptom assessment tool (China) (4 points) |
| 2014 | Kong Suping | 29 | 28 | (GV20,CV12, ST25, ST36, SP9, ST39)/pinaverium bromide 50mg tid | 38±11 | 38±11 | IBS-D | ROME III | 26 | 23 | 4 weeks | 3 | Mixed | China | 0 | 0 | symptom assessment tool (China) (4 points) |
| 2014 | Liu Shuying | 30 | 30 | (GV20,EX-HN3,CV12,ST25,ST37,ST39)/pinaverium bromide 50mg tid | 41.4±11.8 | 41.77±8.99 | IBS-D | ROME III | 27 | 23 | 4 weeks | 1 | Mixed | China | 0 | 0 | symptom assessment tool (China) (4 points) |
| 2013 | Wu Yuanjian | 30 | 30 | (ST25, ST36, ST37, SP6, CV8)/pinaverium bromide 50mg tid | 37.9±10.2 | 39.8±11.2 | IBS-D | ROME III | 26 | 24 | 4 weeks | 1 | Mixed | China | 0 | 0 | symptom assessment tool (China) (4 points) |
| 2012 | Pei Lixia | 30 | 30 | (ST25, ST36, ST37, SP6, LR3, GV20, EX-HN3)/pinaverium bromide 50mg tid | 40.9±10.6 | 37.93±11.45 | IBS-D | ROME III | 27 | 24 | 4 weeks | 3 | Mixed | China | 0 | 0 | symptom assessment tool (China) (4 points) |
| 2013 | LI HAO | 35 | 35 | (ST 25, ST 36, ST37, SP6, LR3, GV20, GV29)/pinaverium bromide 50mg tid | 37.9±11.5 | 39.1±11.8 | IBS-D | ROME III | 33 | 27 | 4 weeks | 5 | Mixed | China | 0 | 0 | symptom assessment tool (China) (4 points) |
| 2011 | Sun | 30 | 30 | (ST 25, ST 36, SP6,LR3,DU20,EX-HN 3 and ST 37)/pinaverium bromide (50mg tid) | 38.81±11.8 | 38.59±11.45 | IBS-D | ROME III | 27 | 24 | 4 weeks | 3 | Mixed | China | 0 | 0 | symptom assessment tool (China) (4 points) |
| 2010 | Shi | 32 | 38 | (ST 25, ST 36, BL 20, BL 21, BL 23, BL 25 and ST 37)/pinaverium bromide (50mg tid) | 38.51±14.65 | 38.68±15.72 | IBS-D | ROME III | 26 | 20 | 4 weeks | 6 | Mixed | China | 0 | 0 | Overall IBS symptom VAS score (10 points) |
| 2017 | Lembo (1) | 426 | 427 | Eluxadoline 100mg /placebo BID | 44.4±13.9 | 45.8±14.1 | IBS-D | ROME III | 107 | 73 | 12 weeks | 7 | Mixed | United States | 500/859 | 450/808 | IBS-D global symptom score, Bristol Stool Form Scale |
| 2017 | Lembo (2) | 383 | 382 | Eluxadoline 100mg /placebo BID | 45.7±13.3 | 47.1±13.8 | IBS-D | ROME III | 113 | 62 | 12 weeks | 7 | Mixed | United States | NS | NS | IBS-D global symptom score, Bristol Stool Form Scale |
| 2013 | DOVE | 163 | 159 | Eluxadoline 100mg /placebo BID | 43.6±10.9 | 44.6±12.5 | IBS-D | ROME III | 46 | 22 | 12 weeks | 7 | Mixed | United States | 73/165 | 78/159 | IBS Global Symptom score, IBS-SSS |
| 2015 | Liang Zheng | 218 | 209 | Pinaverium 50mg tid/placebo | 36.9±11.8 | 36.6±12.6 | IBS | ROME III | 131 | 71 | 4 weeks | 7 | Mixed | China | 40/218 | 32/209 | Bowel Symptom Scale (10 points), Bristol stool form scale |
| 1977 | Levy | 30 | 30 | Pinaverium 50mg tid/placebo | NS | NS | IBS | Clinical | 24 | 17 | 2 weeks | 3 | Mixed | French | NS | NS | NS |
| 1981 | Delmont | 25 | 25 | Pinaverium 50mg tid/placebo | NS | NS | IBS | Clinical | 19 | 17 | 4 weeks | 4 | Mixed | French | NS | NS | NS |
| 2005 | Lin Chang | 131 | 128 | Alosetron 1mg/Vitamin C BID | 44±12 | 43±12 | IBS-D | ROME I | 69 | 51 | 12 weeks | 7 | Mixed | United States | 86/130 | 65/128 | Average abdominal pain and stool consistency score (5 points) |
| 2004 | William D.Chey | 279 | 290 | Alosetron 1mg/Vitamin C BID | 46.2±13.5 | 46.9±12.9 | IBS-D | Clinical | 144 | 119 | 48 weeks | 7 | Women | United States | 297/348 | 261/362 | Average abdominal pain and stool consistency score (5 points) |
| 2004 | Lembo (1) | 147 | 135 | Alosetron 2mg/Vitamin C BID | 48.9±15.5 | 49.4±13.8 | IBS-D | Rome II | 100 | 62 | 12 weeks | 6 | Female | United States | 145/246 | 127/246 | IBS-D global symptom score, Average stool consistency scores (5 points) |
| 2004 | Lembo (2) | 457 | 219 | Alosetron 2mg/Vitamin C BID | 48.8±14.0 | 48.6±13.6 | IBS-D | Rome II | 320 | 99 | 12 weeks | 6 | Female | United States | NS | NS | IBS-D global symptom score, Average stool consistency scores (5 points) |
| 2007 | Krause | 177 | 176 | Alosetron 1mg/Vitamin C BID | 43 | 43 | IBS-D | ROME II | 76 | 54 | 12 weeks | 7 | Women | United States | 102/176 | 94/176 | IBS-D global symptom score, Average stool consistency scores (5 points) |
| 2011 | Lee KJ | 175 | 168 | Ramosetron 5ug Qd/Placebo | 43.4±12.1 | 45±13.1 | IBS-D | Rome III | 65 | 64 | 4 weeks | 3 | Male | Korea | 69/147 | 77/149 | IBS symptoms (5 points), Bristol Stool Form Scale |
| 2008 | Matsueda (1) | 297 | 104 | Ramosetron 1ug Qd, 5ug Qd, 10ug Qd/Placebo | 40.3±11.8 | 38.4±9.56 | IBS-D | Rome II | 110 | 28 | 12 weeks | 6 | Mixed | Japan | 177/309 | 61/108 | IBS symptoms (5 points), Bristol Stool Form Scale |
| 2015 | Fukudo S AB | 307 | 102 | Ramosetron 1.25ug Qd, 2.5ug Qd, 5ug Qd/placebo | 40.9±10.6 | 40.2±10.1 | IBS-D | Rome III | 121 | 29 | 12 weeks | 3 | Female | Japan | NS | NS | IBS symptoms (5 points), Bristol Stool Form Scale |
| 2016 | Fukudo S | 292 | 284 | Ramosetron 2.5ug Qd/Placebo | 41.4±11.8 | 41.5±12.0 | IBS-D | Rome III | 148 | 91 | 12 weeks | 7 | Female | Japan | 154/292 | 118/284 | IBS symptoms (5 points), Bristol Stool Form Scale |
| 2008 | Matsueda (2) | 263 | 265 | Ramosetron 5ug Qd/Placebo | 40.7±11.21 | 41.8±11.70 | IBS-D | Rome II | 124 | 72 | 12 weeks | 5 | Mixed | Japan | 163/270 | 141/269 | IBS symptoms (5 points), Bristol Stool Form Scale |
| 2014 | Fukudo S | 147 | 149 | Ramosetron 5ug Qd/Placebo | 40.9±10.6 | 40.2±10.1 | IBS-D | Rome III | 58 | 26 | 12 weeks | 7 | Male | Japan | 13/175 | 6/168 | IBS symptoms (5 points), Bristol Stool Form Scale |
| 2008 | Lembo | 191 | 197 | Rifaximin 550mg bid/Placebo | NS | NS | IBS-D | Rome II | 100 | 87 | 2 weeks | 4 | Mixed | Multicenter | NS | NS | IBS-D global symptom score, IBS-associated bloating |
| 2011 | Primentel (1) | 309 | 314 | Rifaximin 550mg tid/Placebo | 46.2±15.0 | 45.5±14.6 | Non-C | Rome II | 126 | 98 | 2 weeks | 7 | Mixed | Multicenter | 264/624 | 296/634 | IBS symptoms (5 points), Bristol Stool Form Scale |
| 2011 | Primentel (2) | 315 | 320 | Rifaximin 550mg tid/Placebo | 45.9±13.9 | 46.3±14.6 | Non-C | Rome II | 128 | 103 | 2 weeks | 7 | Mixed | Multicenter | NS | NS | IBS symptoms (5 points), Bristol Stool Form Scale |
| 2017 | Lowe | 43 | 36 | Acupuncture/sham | 42±15 | 43±15 | IBS | Rome I | 23 | 15 | 4 weeks | 7 | Mixed | Canada | 0 | 0 | IBS Symptoms (5 points), SF-36, IBS-36 |
| 2000 | Catherine Lowe | 28 | 22 | Acupuncture/sham | NS | NS | IBS | NS | 16 | 10 | 4 weeks | 3 | Mixed | Canada | NS | NS | NS |
| 2009 | Anthony J | 78 | 77 | Acupuncture/sham | 37.5±14.6 | 38.9±14.1 | IBS | Rome II | 32 | 24 | 3 weeks | 6 | Female | United States | 0 | 0 | IBS-Symptom severity scale, IBS-AR, QOL |
| 2005 | Forbes | 27 | 32 | Acupuncture/sham | 43 | 44.4 | IBS | Rome+Manning | 13 | 10 | 12 weeks | 7 | Mixed | UK | 0 | 0 | global symptom score, Bristol stool scale |
|
